NEXT GENERATION DNA SEQUENCING NETWORK RESOURCE

下一代 DNA 测序网络资源

• 批准号: 7909470
• 负责人: Richard M. Weinshilboum
• 金额: $ 51.9万
• 依托单位: MAYO CLINIC ROCHESTER
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-07-01 至 2015-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7909470
• 关键词: Arts; Biological; Clinic; Collaborations; Cytochrome P450; DNA; DNA Resequencing; DNA Sequence; Discipline; Evaluation; Foundations; Funding; Gene Family; Genes; Genome; Genomics; Genotype; Goals; Human Genome; Letters; Link; Medical; Medicine; Mind; Outcome; Peer Review; Pharmacogenomics; Process; Protocols documentation; Research; Research Infrastructure; Resources; Science; Series; Signal Transduction; Techniques; Technology; base; college; cost; design; experience; genome sequencing; genome wide association study; genome-wide; next generation; programs

OVERALL SUMMARY AND SPECIFIC AIMS: NETWORK RESOURCE This component of the Mayo Clinic PGRN renewal application represents a request for the funding of a "Network Resource" designed to provide the entire PGRN with access to the latest techniques In the rapidly evolving field of "Next Generation" DNA sequencing. Access would be provided through a recurring, peer-reviewed process available to all PGRN Centers similar to the current "PGRN-RIKEN" process for obtaining access to pharmacogenomic GWAS genotyping through the PGRN-RIKEN collaboration. This proposed "PGRN Nehwork Resource" is one of three coordinated applications from current PGRN Centers, all with similar goals - clearly indicating an unmet need in pharmacogenomic research - a need emphasized by the letters of support from current PGRN Centers that are attached to this application. Those letters were sent by eight different PGRN research centers. Although pharmacoqenomics has always required access to DNA sequencing, that need has been accentuated bv recent dramatic changes in DNA seguencing technology and bv the eguallv dramatic outcomes of the application of genome-wide approaches to pharmacogenomics. Each of these proposals is designed to provide a "link" between the PGRN and a large, experienced Genomics Center with expertise in both the application and the evaluation of DNA sequencing technology. The issue is not whether pharmacogenomics as a discipline requires access to the very latest in rapidly evolving DNA sequencing techniques, but only how to achieve that goal in a way that will best advance the science while being affordable and open to all PGRN Centers. Specifically, the Mayo PGRN is proposing that a formal collaborative relationship be established with the Baylor College of Medicine (BCM)-Human Genome Sequencing Center (HGSC), one of three NHGRIsupported large genome centers - with an open, protocol-based selection process similar to the well established and highly successful PGRN-RIKEN process for the selection of PGRN pharmacogenomic GWAS genotyping projects performed in collaboration with RIKEN. The initial focus of the Mayo PGRN-sponsored "Next Generation" DNA sequencing Network Resource would be on sequencing large contiguous regions of the genome. In some cases, this will involve complete resequencing of large genes or tandemly repeated gene families or even entire gene families, e.g., the "CYPome", all cytochrome P450 genes. In other cases, it wilt involve focused resequencing across "SNP signals" observed during pharmacogenomic GWA studies - in many cases, GWA studies made possible by the PGRN-RIKEN collaboration, thus building on a foundation established by that very successful program. Since the review panel for these applications will evaluate a series of Network Resource applications for access to Next Generation DNA sequencing, it should be emphasized that the Mayo PGRN looks upon these efforts as complementary. Therefore, it is possible that reviewers may conclude that some "combination" of these proposals should be supported. All of these proposals share; ¿ A recognition of the critical need for access to rapidly evolving DNA sequencing techniques in order to advance the science of pharmacogenomics. ¿ A recognition that established Genome Centers have the requisite experience, expertise and infrastructure required to make this effort succeed. ¿ A recognition that the "process" for access to Next Generation DNA sequencing will have to be open to all PGRN centers, based on scientific significance and feasibility. The cost associated with these studies would be covered primarily by funding available to the "Network Resource".

总体概述和具体目标：网络资源 马约诊所PGRN更新申请的这一组成部分代表了对以下项目的资助请求： “网络资源”，旨在为整个PGRN提供最新技术。 快速发展的“下一代”DNA测序领域。将通过一个 与当前的“PGRN-RIKEN”类似，所有PGRN中心均可使用重复的同行评审流程 通过PGRN-RIKEN获得药物基因组学GWAS基因分型的过程 协作这个提议的“PGRN网络资源”是三个协调应用程序之一， 目前的PGRN中心，都有类似的目标-明确表明药物基因组学研究的需求未得到满足 - 需要强调的支持信，从目前的PGRN中心是附在这个应用程序。 这些信件是由八个不同的PGRN研究中心发送的。尽管药物基因组学一直 需要获得DNA测序，这种需要已经强调了最近的戏剧性变化，DNA 测序技术与全基因组方法应用的同样显著的结果 药物基因组学这些建议中的每一个都旨在提供PGRN和 大型，经验丰富的基因组学中心，在DNA的应用和评估方面具有专业知识 测序技术问题不在于药物基因组学作为一门学科是否需要获得 这是快速发展的DNA测序技术的最新进展，但只是如何以一种 最好的推进科学，同时负担得起，并开放给所有PGRN中心。 具体而言，马约PGRN建议与以下机构建立正式的合作关系： 贝勒医学院（Baylor College of Medicine）-人类基因组测序中心（Human Genome Sequencing Center，HGSC），三个NHGRI支持的中心之一 大型基因组中心-具有开放的，基于协议的选择过程，类似于井 已建立并高度成功的PGRN-RIKEN方法，用于选择PGRN药物基因组学GWAS 与RIKEN合作进行的基因分型项目。由马约赞助的PGN最初的重点是 “下一代”DNA测序网络资源将对大的连续区域进行测序， 基因组在某些情况下，这将涉及大基因的完全重测序或串联重复 基因家族或甚至整个基因家族，例如，“CYPome”，所有细胞色素P450基因。在其他情况下，它 将涉及在药物基因组学GWA研究中观察到的“SNP信号”的集中重测序， 在许多情况下，GWA研究是由PGRN-RIKEN合作实现的，因此建立在一个基础上， 由这个非常成功的项目建立起来的。由于这些申请的审查小组将评估一个 一系列网络资源应用程序访问下一代DNA测序，它应该是 强调马约PGRN将这些努力视为补充。因此，有可能 审查人员可能会得出结论，这些建议的某种“组合”应该得到支持。所有这些 建议分享; 认识到迫切需要获得快速发展的DNA测序技术， 推进药物基因组学的发展 认识到已建立的基因组中心具有必要的经验，专业知识和 基础设施，使这一努力取得成功。 认识到获得下一代DNA测序的“过程”必须向公众开放， 所有PGRN中心，基于科学意义和可行性。与此相关的成本 研究经费将主要由“网络资源”提供的资金支付。